GeneDx Q4 revenue jumps 27% on genome, exome test demand

GeneDx Holdings

23/02/2026 11:39

Overview

Genomic diagnostics firm's Q4 2025 revenue rose 27% yr/yr

Exome and genome test revenue grew 32% yr/yr

Adjusted net income for Q4 2025 was $4.4 mln

Outlook

GeneDx reaffirms 2026 revenue guidance of $540 to $555 mln

Company expects 33-35% growth in exome and genome revenue for 2026

GeneDx anticipates adjusted gross margin of at least 70% in 2026, and adjusted net income to be positive

Result Drivers

EXOME AND GENOME TESTS - Revenue from exome and genome tests increased 32% yr/yr, driven by higher test volumes

GROSS MARGIN IMPROVEMENT - Adjusted gross margin improved to 71%, reflecting efficient cost management

MARKET EXPANSION - Expansion into general pediatrics and prenatal diagnostics contributed to revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted Net Income
$4.40 mln
Q4 Net Income
-$17.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for GeneDx Holdings Corp is $170.00, about 107.2% above its February 20 closing price of $82.06

The stock recently traded at 122 times the next 12-month earnings vs. a P/E of 125 three months ago

Press Release: ID:nBw2rxdF8a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)